April 2019


Quanta SC+ confirmed as safe and easy to use.

Alcester, Warwickshire, UK.  15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International, […]

Quanta SC+ confirmed as safe and easy to use. Read More »

Cancer Killers

Fusion Raises $105m in Series B Financing.

Hamilton, Ontario and Dublin, Ireland.  April 2nd 2019.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed Advisors. Seroba participated in the round alongside new investors including Perceptive Advisors, Pivotal

Fusion Raises $105m in Series B Financing. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top